Cilengitide inhibits metastatic bone colonization in a nude rat model

Area of Science:

• Oncology
• Integrin biology
• Bone metastasis research

Background:

• Integrins αvβ3 and αvβ5 are implicated in breast cancer bone metastasis pathogenesis.
• Early intervention targeting these integrins may impact metastatic progression.

Purpose of the Study:

• To investigate the effects of the αvβ3/αvβ5 integrin inhibitor cilengitide on early bone metastatic colonization.
• To assess cilengitide's impact on breast cancer cell behavior, osteoclast activity, and bone vasculature in vivo.

Main Methods:

• In vitro studies: assessed MDA-MB-231 cell proliferation, migration, invasion, and osteoclast activity with cilengitide.
• In vivo studies: utilized nude rats with induced bone metastases, treated with cilengitide for 30 days.
• Imaging techniques: employed flat-panel volumetric computed tomography (VCT) and magnetic resonance imaging (MRI), including dynamic contrast-enhanced (DCE-) MRI, to monitor metastatic changes and vasculature.

Main Results:

• In vitro, cilengitide decreased MDA-MB-231 cell proliferation, migration, invasion, and osteoclast activity.
• In vivo, cilengitide did not prevent bone metastasis but reduced osteolytic lesion and soft tissue tumor volumes.
• DCE-MRI revealed significant vascular remodeling, including decreased blood volume and increased permeability, after cilengitide treatment.

Conclusions:

• Cilengitide demonstrates therapeutic potential in early-stage breast cancer bone metastasis.
• The drug affects tumor cells, osteoclasts, and tumor vasculature, leading to reduced skeletal lesion size.
• Targeting αvβ3/αvβ5 integrins with cilengitide offers a strategy to manage experimental bone metastases.